Misplaced Pages

This is an old revision of this page, as edited by AnomieBOT (talk | contribs) at 16:59, 23 December 2011 (Dating maintenance tags: {{No references}}). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Verteporfin" – news · newspapers · books · scholar · JSTOR (December 2011) (Learn how and when to remove this message)

Verteporfin

Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a607060
Routes of administration	Intravenous
ATC code	S01LA01 (WHO)
Identifiers
IUPAC name 3-octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
CAS Number	129497-78-5
PubChem CID	5362420
DrugBank	APRD01290
ChemSpider	21106402
UNII	0X9PA28K43
KEGG	D01162
ChEBI	CHEBI:60775
ChEMBL	ChEMBL1200573
CompTox Dashboard (EPA)	DTXSID2045604
Chemical and physical data
Formula	C41H42N4O8
Molar mass	718.794 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES COC(=O)2C(=C\C=C3\c1cc6nc(cc5nc(cc4nc(cc(n1)23C)C(/C)=C4/CCC(=O)OC)c(CCC(O)=O)c5C)C(/C=C)=C6/C)/C(=O)OC
InChI InChI=1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,33-18-,34-17-,35-19-/t38-,41+/m0/s1 Key:ZCQHFRFEJXRZDF-YWANUUMDSA-N
(what is this?)  (verify)

Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Verteporfin is also used off-label for the treatment of central serous retinopathy.

Administration

Verteporfin is given intravenously, within 15 minutes before laser treatment.

Side effects

Most commonly, blurred vision. Also, photosensitivity; it is advised to avoid exposure to sunlight and unscreened lighting until 48 hours after the injection of verteporfin.

External links

• Novartis website for Visudyne
• Research into using verteporfin to treat pancreatic cancer

• Photosensitizing agents
• Ophthalmology drugs